• Dry Cracked Skin
  • General Dermatology
  • Impetigo
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

AD Endotypes and Outcomes

Opinion
Video

Christopher Bunick, MD, PhD, discusses how a patient’s atopic dermatitis (AD) endotype may alter treatment approaches in the future.

Christopher Bunick, MD, PhD

Associate Professor, Dermatologist

Yale University

Middlebury, Connecticut

Ruth Ann Vleugels, MD, MPD, MBA

Vice-Chair of Academic Affairs

Department of Dermatology at Brigham and Women’s Hospital

Boston, Massachusetts

Program Description: Experts discuss the results of multiple studies analyzing the incident rates and safety of Janus Kinase (JAK) inhibitors in the treatment of atopic dermatitis (AD).

Segment Description: Christopher Bunick, MD, PhD, discusses how a patient’s atopic dermatitis (AD) endotype may alter treatment approaches in the future.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.